Burnett Patrick has demonstrated a clear selling bias in their recent trading activity involving Arcutis Biotherapeutics (ARQT), with no purchases recorded in their latest transactions. Over the past year, Patrick has executed 18 sales totaling approximately $2.12 million, with the largest single sale occurring on February 4, 2026, for $252,747.88. Additional notable dispositions include a $332,851.40 transaction on December 15, 2025, and a $417,144.68 sale on November 6, 2025. The selling has been consistent, with multiple transactions in the six-figure range throughout late 2025 and early 2026, including a $153,629.40 sale on March 2, 2026.
Patrick’s only recorded buys in ARQT were relatively minor, totaling $104,650 and occurring earlier in the period, with the last purchase taking place in mid-2025 alongside sales. The transactions appear to be part of a broader divestment trend, as the majority of recent filings reflect dispositions rather than acquisitions. While some sales were accompanied by small option-related transactions (coded "M"), the overwhelming pattern is one of steady liquidation, with no new equity positions established in recent months. The activity is concentrated solely in ARQT, indicating no diversification across other securities in the reported period.
AI-assisted summary